Novel drugs for older patients with acute myeloid leukemia (Q38241761)

31 August 2017

Novel drugs for older patients with acute myeloid leukemia (English)

1 reference

31 August 2017

1 reference

G Montalban-Bravo

1

1 reference

31 August 2017

G Garcia-Manero

series ordinal

2

1 reference

31 August 2017

language of work or name

1 reference

21 August 2014

1 reference

31 August 2017

1 reference

31 August 2017

29

1 reference

31 August 2017

4

1 reference

31 August 2017

760-769

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2014.244

31 August 2017

0 references

cites work

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions-a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Advances in understanding the leukaemia microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Prognostic relevance of integrated genetic profiling in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

A novel hierarchical prognostic model of AML solely based on molecular mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Questions regarding frontline therapy of acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

DNA methylation as a therapeutic target in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Negative effect of DNA hypermethylation on the outcome of intensive chemotherapy in older patients with high-risk myelodysplastic syndromes and acute myeloid leukemia following myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

5-Aza-2'-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Small doses of ARA-C in the treatment of acute myeloid leukaemia: differentiation of myeloid leukaemia cells?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Discovery and development of clofarabine: a nucleoside analogue for treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Molecular basis for G2 arrest induced by 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine and consequences of checkpoint abrogation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Sapacitabine, the prodrug of CNDAC, is a nucleoside analog with a unique action mechanism of inducing DNA strand breaks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Modeling the temporal evolution of the spindle assembly checkpoint and role of Aurora B kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Drug therapy for acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

The roles of FLT3 in hematopoiesis and leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Mechanisms of resistance to decitabine in the myelodysplastic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Vorinostat induces apoptosis and differentiation in myeloid malignancies: genetic and molecular mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

A phase 2 study of vorinostat in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

LBH-589 (panobinostat) potentiates fludarabine anti-leukemic activity through a JNK- and XIAP-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Understanding and targeting cancer stem cells: therapeutic implications and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

EZH2 in normal and malignant hematopoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Ecotropic viral integration site 1, stem cell self-renewal and leukemogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Efficacy and safety of vismodegib in advanced basal-cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

U.S. Food and Drug Administration approval summary: omacetaxine mepesuccinate as treatment for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Vosaroxin: a new valuable tool with the potential to replace anthracyclines in the treatment of AML?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Effect of ON 01910.Na, an anticancer mitotic inhibitor, on cell-cycle progression correlates with RanGAP1 hyperphosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Randomized phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.244

AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo

21 January 2018

1 reference

12 December 2020

Molecular cloning, expression, and chromosomal localization of a human gene encoding the CD33 myeloid differentiation antigen

1 reference

12 December 2020

Low dose cytosine arabinoside: partial remission of acute myeloid leukaemia without evidence of differentiation induction

1 reference

12 December 2020

Expression of normal myeloid-associated antigens by acute leukemia cells

1 reference

12 December 2020

Antitumor activity and novel DNA-self-strand-breaking mechanism of CNDAC (1-(2-C-cyano-2-deoxy-beta-D-arabino-pentofuranosyl) cytosine) and its N4-palmitoyl derivative (CS-682)

1 reference

12 December 2020

A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment

1 reference

12 December 2020

Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies

1 reference

12 December 2020

Molecular targeted therapies for cancer: sorafenib mono-therapy and its combination with other therapies (review).

1 reference

12 December 2020

Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system

1 reference

12 December 2020

Identifiers

DOI

10.1038/LEU.2014.244

1 reference

Dimensions Publication ID

31 August 2017

1038363102

0 references

Fatcat ID

release_bkmcipdgpze5npnonjwa6qd7wq

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/bkmcipdgpze5npnonjwa6qd7wq

24 November 2022

mapped directly with Wikidata item

1 reference